Nada Khaled Ameen

Dr. Nada Khaled Ameen

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2026 in The Journal of Vascular Access
Verified
Journal Article
Closed access
NANada Khaled Ameen
Nada Khaled Ameen
AAAmjad I Albadawi
Amjad I Albadawi
SAShatha K Alghamdi
Shatha K Alghamdi
AAAli I Atwi
Ali I Atwi
LALama N Alharbi
Lama N Alharbi
AJAlmamoon I Justaniah
Almamoon I Justaniah
Endovascular arteriovenous fistula (eAVF) creation is a minimally invasive alternative to traditional surgical arteriovenous fistula (sAVF) for hemodialysis access. We conducted a systematic review and meta-analysis to evaluate the clinical outcomes of eAVF and compare them with those of sAVF. A total of 28 studies were included, comprising 20 single-arm eAVF studies and 8 comparative studies, identified through searches of PubMed, MEDLINE, Web of Science, ScienceDirect, Google Scholar, and Cochrane CENTRAL from inception to February 1, 2025. Outcomes assessed included technical success, maturation rate, primary patency, reintervention, and complications. The pooled technical success rate of eAVF was 97%, with a maturation rate of 77%. Primary patency rates were 64% at 6 months and 77% at 12 months. The overall complication rate was low (9%), although moderate to high heterogeneity was observed across several outcomes. Device subgroup analyses demonstrated numerical differences between Ellipsys and WavelinQ systems with overlapping confidence intervals. In comparative studies, no statistically significant differences were observed in maturation rate or primary patency; however, eAVF was associated with numerically higher reintervention rates and lower complication rates. These findings suggest that eAVF represents a safe and effective alternative to surgical AVF in appropriately selected patients, while highlighting the importance of careful patient selection and post-procedural surveillance given the heterogeneity of existing evidence.

13 October 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
Abdullah AlmaqhawiAbdullah Almaqhawi
Abdullah Almaqhawi
AAAHMED ALSAIF
AHMED ALSAIF
HAHamza Ashraf
Hamza Ashraf
MAMiad Alhamrani
Miad Alhamrani
NANada Khaled Ameen
Nada Khaled Ameen
AAAli Ahmed K Albahrani
Ali Ahmed K Albahrani
Background/Objectives: Dapagliflozin is a foundational chronic heart failure therapy, but whether it retains benefit when initiated early during hospitalization for acute heart failure (AHF) remains uncertain. Methods: We searched MEDLINE, Embase, Scopus, and CENTRAL from inception to 26 January 2026 for randomized trials comparing early initiation of dapagliflozin 10 mg once daily with standard therapy in adults hospitalized for AHF (PROSPERO CRD420261364466). Two reviewers independently performed screening, extraction, and risk-of-bias assessment. Outcomes were pooled under random-effects models with Knapp–Hartung adjustment. Results: Ten trials enrolling 3507 participants (1769 in the dapagliflozin group and 1738 in the control group) were eligible. Dapagliflozin significantly reduced all-cause mortality (RR 0.67, 95% CI 0.52–0.86) and urinary tract infections (RR 0.52, 95% CI 0.35–0.76), while no significant differences were observed in cardiovascular death, MACEs, heart failure hospitalization, all-cause readmission, length of hospital stay, or body weight. Dapagliflozin was not associated with a significant increase in acute kidney injury, hypotension, or hypoglycemia, supporting a favorable safety profile. Conclusions: In adults hospitalized with acute heart failure (AHF), dapagliflozin significantly reduced all-cause mortality but not heart failure hospitalization during follow-up. Larger, adequately powered trials in patients with AHF, with prespecified analyses according to the timing of dapagliflozin initiation, are warranted.

23 October 2026 in Medicine
Verified
Journal Article
Open access
MAMohammed Alfawaz
Mohammed Alfawaz
DBDareen Bajamaan
Dareen Bajamaan
LALama Alghamdi
Lama Alghamdi
YAYara Alorfi
Yara Alorfi
SKSaud Khared
Saud Khared
SAShaima Altowairqi
Shaima Altowairqi
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) are increasingly prevalent liver diseases closely linked to obesity, type 2 diabetes mellitus, and cardiometabolic risk. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may improve hepatic and metabolic outcomes through weight reduction, improved glycemic control, and reductions in hepatic steatosis. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of GLP-1 RAs in adults with MASLD or MASH. Methods: A systematic review and meta-analysis was conducted in accordance with PRISMA 2020 guidelines. PubMed, Web of Science, Scopus, Google Scholar, and the Cochrane Central Register of Controlled Trials were searched for English-language studies published between January 2019 and December 2025. Eligible studies included adults with MASLD or MASH treated with GLP-1 RAs and reporting hepatic, metabolic, or safety outcomes. Pooled estimates were calculated using random-effects models. Results: Nine studies involving 795 participants were included. GLP-1 RA therapy was associated with significant reductions in liver fat content (mean difference [MD]: −3.17; 95% CI: −4.06 to −2.29), body weight (MD: −4.68; 95% CI: −6.88 to −2.47), alanine aminotransferase (MD: −15.17; 95% CI: −21.29 to −9.05), aspartate aminotransferase (MD: −9.89; 95% CI: −13.65 to −6.13), and HbA1c (MD: −0.78; 95% CI: −1.07 to −0.49). Adverse events were more frequent with GLP-1 RAs, particularly nausea and vomiting, while serious adverse events did not differ significantly between groups. Conclusion: GLP-1 RAs are associated with meaningful improvements in hepatic steatosis, liver enzymes, body weight, and glycemic control in patients with MASLD or MASH. These findings support their potential role, particularly in patients with coexisting obesity or type 2 diabetes. However, further long-term, adequately powered trials are needed to clarify their effects on fibrosis regression, histological outcomes, and liver-related clinical events.